Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

Completed

• Conditions: Hemorrhagic Hereditary Telangiectasia; HHT
• Interventions: Other: bevacizumab treatment

• Registration Number: NCT06039124
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT.

We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment.

We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-01
• Primary Completion: 2022-01-01
• Study Completion: 2022-08-01
• Status Verified: 2023-09
• Study First Submitted: 2023-09-08
• Study First Submitted QC: 2023-09-08
• Last Update Submitted: 2023-09-08
• Study First Posted: 2023-09-15
• Last Update Posted: 2023-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Patient included in BABH study

Exclusion Criteria

• Patients opposition

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HHT patients previously included in BABH study	bevacizumab treatment	Clinical and therapeutic follow-up of HHT patients for one year after the end of a clinical trial using bevacizumab.

Primary Outcome Measures

Name	Time	Method
Bevacizumab treatment description after end of BABH study	12 months	Number of patients who received bevacizumab after BABH study. Among patients who received bevacizumab in BABH study: description of re-treatments.; In patients who received placebo in BABH study: description of treatments.

Trial Locations

Locations (3)

CHU de Montpellier-Hôpital St Eloi; 🇫🇷 Montpellier, France

Hôpital Ambroise Paré; 🇫🇷 Boulogne Billancourt, France

Service de Médecine Interne et Maladies Vasculaires + Service Neuropédiatrie et neurochirurgie de l'enfant - CHU Angers; 🇫🇷 Angers, France